T2 Biosystems, a leading provider of rapid diagnostic tools for sepsis-causing pathogens and antibiotic resistance genes, announced that they will be releasing their financial results for the first quarter of 2024 and providing updates on their business after the market closes on Monday, May 6th, 2024. A conference call hosted by company management will begin at 4:30 p.m. Eastern Time.
Investors interested in attending the conference call can access a live and archived webcast of the event on the Investor page of the T2 Biosystems website at www.t2biosystems.com in the Events & Presentations section. To listen to the conference call via phone, participants can dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with passcode 160751, approximately ten to five minutes before the scheduled start time.
T2 Biosystems is committed to improving patient care and reducing healthcare costs by enabling clinicians to diagnose patients faster than ever before with their innovative products such as T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, T2Resistance Panel, and T2Biothreat Panel. The company’s proprietary T2 Magnetic Resonance (T2MR) technology has been instrumental in revolutionizing rapid diagnostics in this field. With an active pipeline of future products including U.S.-based T2Resistance Panel, Candida auris test, and T2Lyme Panel, T2 Biosystems continues to push boundaries in this rapidly evolving field of diagnostics for infectious diseases.
For more information about T
